Woman using digital 3D projection of a human brain 3D rendering

(© sdecoret - stock.adobe.com)

CINCINNATI, Ohio – A new study is bringing hope to the millions of people living with brain cancer. Researchers from the University of Cincinnati found that manipulating the electricity cells use could help to treat a deadly brain tumor known as glioblastomas.

Human cells use electricity to line up materials called mitotic spindles to prepare them for cell division and growth. By creating an electric field to counteract the cell’s electricity, researchers could target and block tumor growth. The treatment flows through a set of electrodes called electrical arrays that patients wear like a cap on their heads.

“These arrays point the electric fields at the area of the brain tumor,” says Kyle Wang, MD, a radiation oncologist and assistant professor at the UC College of Medicine in a university release. “It’s been shown to actually improve how many people survive this disease.”

The mesh cap, called the Optune device, stays on the patient's head for at least 18 hours a day. The longer someone wears the device, the more likely they are to see better treatment outcomes, according to the researchers. However, the team adds that patients should not have to wear the Optune device for the rest of their lives. Rather, they encourage patients to wear it until they don't want to, or until it's no longer effective.

Living longer after electrical therapy

The U.S. Food and Drug Administration has approved the Optune device for use as a treatment for patients with glioblastoma following surgery and radiation and at the same time as chemotherapy treatments. Dr. Wang says that previous research found people wearing the device lived 30 to 50 percent longer than people who did not have access to it.

Dr. Wang is leading a new clinical trial called TRIDENT to study if early treatment of the Optune device could lead to better health outcomes. The study plans to enroll 950 patients, with half using the Optune device at the same time as radiation treatment and the other half using it along with chemotherapy.

cancer electricity
The Optune device, left, shown with carrying case, connecting cables and electrical arrays that are worn on the patient's head. (Reproduced with permission from Novocure GmbH ©2021 Novocure GmbH)

The most common side-effects Optune device users experience are skin irritation and logistical difficulties.

“It takes a lot of care to figure out how to wear something 18 hours a day that has to plug in to a portable electric source, but every patient that uses the Optune device gets a designated device specialist who makes sure they have almost 24/7 access to questions about how to use this device, how to bring it with them on trips and how to continue living well using this device that’s been shown to improve survival,” Dr. Wang says.

“It’s been a long time since something was invented that works for this type of disease. It’s really fulfilling to have patients that are looking for other options or basically reasons to have hope. I think this trial as well as the device is one of the more impactful discoveries for glioblastoma in decades.”

About Jocelyn Solis-Moreira

Jocelyn is a New York-based science journalist whose work has appeared in Discover Magazine, Health, and Live Science, among other publications. She holds a Master's of Science in Psychology with a concentration in behavioral neuroscience and a Bachelor's of Science in integrative neuroscience from Binghamton University. Jocelyn has reported on several medical and science topics ranging from coronavirus news to the latest findings in women's health.

Our Editorial Process

EdNews publishes digestible, agenda-free, transparent research summaries that are intended to inform the reader as well as stir civil, educated debate. We do not agree nor disagree with any of the studies we post, rather, we encourage our readers to debate the veracity of the findings themselves. All articles published on EdNews are vetted by our editors prior to publication and include links back to the source or corresponding journal article, if possible.

Our Editorial Team

Steve Fink

Editor-in-Chief

Chris Melore

Editor

Sophia Naughton

Associate Editor